Tapentadol is a centrally-acting synthetic opioid analgesic of the phenylpropylaminopentane class. First approved by the FDA in 2008, it possesses a dual mechanism of action as both a mu-opioid receptor agonist and norepinephrine reuptake inhibitor. Its analgesic potency falls roughly between tramadol and morphine. Tapentadol carries a high addiction potential and significant risk of respiratory depression in overdose; combining it with other depressants or stimulants is strongly discouraged.
Tapentadols molecular structure diagram from the DrugsPRO substance library.
Also known as: Yantil, Nucynta, Palexia, Yantil sr, Palexia sr
Classification
Chemical: Opioid
Psychoactive: Depressant
Tag: Habit-Forming
Tag: Phenylpropylamine
Tag: Phenylpropylaminopentane
Effects
Sleepiness
Pupil Constriction
Respiratory Depression
Sedation
Muscle Relaxation
Pain Relief
Euphoria
Mood Enhancement
Mood Lift
Dizziness
Anxiety
Sadness
Dulled Perception
Blurred Vision
Disinhibition
Auditory Hallucination
Internal Music
Sound Amplification
Routes of Administration
Oral
Dosage
Heavy: 250 mg+/day
Light: 25 – 50 mg
Common: 100Р0 mg/day (split q12h)
Strong: 200Х0 mg/day (split q12h)
Threshold: 25 mg
Duration
Onset: 0.2-0.5 h
Comeup: 0.5-0.75 h
Peak: 1-2 h
Offset: 10-12 h
After Effects: 12-24 h
Total Duration: 10-12 h
Harm Reduction
Check interactions before mixing substances, pay attention to dose spacing and hydration, and treat all dosage guidance as approximate rather than guaranteed safe.
Sources
Substance data is aggregated from the following public harm-reduction and reference sources.
This static page is intended as a readable non-JS and prerender-friendly library export.
Get the full DrugsPRO experience
Open the interactive DrugsPRO app for search, saved items, interactions, and deeper harm reduction tools.
Get the PRO test kit. The simple, quick and reliable drug checking test kit. Visit https://protestkit.eu
Tapentadol - DrugsPRO vielu ceļvedis
Tapentadol: Tapentadol is a centrally-acting synthetic opioid analgesic of the phenylpropylaminopentane class. First approved by the FDA in 2008, it possesses a dual mechanism of action as both a mu-opioid receptor agonist and norepinephrine reuptake inhibitor. Its analgesic potency falls roughly be